Nakata, D., Masaki, T., Tanaka, A., Yoshimatsu, M., Akinaga, Y., Asada, M.,…Kusaka, M. (2014). Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice. European Journal of Pharmacology, 723, 167-174.
MacLean, D. B., Shi, H., Faessel, H. M., & Saad, F. (2015). Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. The Journal of Clinical Endocrinology & Metabolism, 100(12), 4579-4587.
AUA 2016 prostate cancer oral presentation by Dr. Neal D. Shore (April 2016). Testosterone Lowering, PSA Response, and Quality of Life in Patients with Advanced Hormone-Sensitive Prostate Cancer Receiving TAK-385, an Oral GnRH Antagonist: Phase 2 Interim Analysis.
ASCO GU 2016 prostate cancer poster presentation by Fred Saad. Second interim analysis results from a phase 2 trial of TAK-385, an oral GnRH antagonist, in patients with prostate cancer.
Lee, D., Park, H. G., Yoon, B., & Choi, D. (2016). Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis. Obstetrics & Gynecology Science, 59(1), 32.
Barbieri, R. L. (1992). Hormone Treatment of Endometriosis. Obstetrical & Gynecological Survey, 47(9), 645-646.
Divasta, A. D., & Laufer, M. R. (2013). The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Current Opinion in Obstetrics and Gynecology, 25(4), 287-292.
Chwalisz, K., Surrey, E., & Stanczyk, F. Z. (2012). The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy with Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis. Reproductive Sciences, 19(6), 563-571.
Wu, D., Hu, M., Hong, L., Hong, S., Ding, W., Min, J.,…Guo, W. (2014). Clinical efficacy of add-back therapy in treatment of endometriosis: A meta-analysis. Archives of Gynecology and Obstetrics, 290(3), 513-523.
MacLean, D. B., Matsui, H., Suri, A., Neuwirth, R., & Colombel, M. (2014). Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies. The Journal of Clinical Endocrinology & Metabolism, 99(8).
Abbara, A., Jayasena, C. N., Christopoulos, G., Narayanaswamy, S., Izzi-Engbeaya, C., Nijher, G. M.,…Dhillo, W. S. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. The Journal of Clinical Endocrinology & Metabolism, 100(9), 3322-3331.